Overall, participants with predicted deleterious variants in either gene exhibited less severe clinical phenotypes compared to participants with variants in BMPR2. Carriers of both KLK1 and GGCX variants were older at PAH onset and had decreased MPAP, increased CO, and decreased PVR compared to BMPR2 carriers (Table 3). This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.